RRR-γ-tocopherol induces human breast cancer cells to undergo apoptosis via death receptor 5 (DR5)-mediated apoptotic signaling

Cancer Letters

Volumn 259, Issue 2, 2008, Pages 165-176

  Yu, Weiping ^a   Park, Sook Kyung ^a   Jia, Li ^a   Tiwary, Richa ^a   Scott, Wenjun W ^a   Li, Jing ^a   Wang, Pei ^a   Simmons Menchaca, Marla ^a   Sanders, Bob G ^a   Kline, Kimberly ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Apoptosis; DR5; Human breast cancer cells; RRR tocopherol; TRAIL; Vitamin E

Indexed keywords

CASPASE 8; CASPASE 9; CYTOCHROME C; DEATH RECEPTOR 5; GAMMA TOCOPHEROL; MESSENGER RNA; PROTEIN BAX; PROTEIN BID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SENSITIZATION; SIGNAL TRANSDUCTION;

ALPHA-TOCOPHEROL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BREAST NEOPLASMS; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; GAMMA-TOCOPHEROL; HUMANS; MAMMARY GLANDS, HUMAN; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; PERMEABILITY; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VITAMINS;

EID: 37049025780     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.10.008     Document Type: Article

References (39)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics. CA Cancer J. Clin. 57 (2007) 43-66
2. Zhao X., Li L., and Wang Z. Chemoprevention of breast cancer: current status and future prospects. Front Biosci. 11 (2006) 2249-2256
3. Jiang Q., Christen S., Shigenaga M.K., and Ames B.N. Gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention. Am. J. Clin. Nutr. 74 (2002) 714-722
4. Bieri J.G., and Evarts R.P. Gamma tocopherol: metabolism, biological activity and significance in human vitamin E nutrition. Am. J. Clin. Nutr. 27 (1974) 980-986
5. Hensley K., Benaksas E.J., Bolli R., Comp P., Grammas P., Hamdheydari L., Mou S., Pye Q.N., Stoddard M.F., Wallis G., Williamson K.S., West M., Wechter W.J., and Floyd R.A. New perspectives on vitamin E: gamma-tocopherol and carboxyelthylhydroxychroman metabolites in biology and medicine. Free Radic. Biol. Med. 36 (2004) 1-15
6. Huang H.Y., Alberg A.J., Norkus E.P., Hoffman S.C., Comstock G.W., and Helzlsouer K.J. Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am. J. Epidemiol. 157 (2003) 335-344
7. Dietrich M., Traber M.G., Jacques P.E., Cross C.E., Hu Y., and Block G.J. Does gamma-tocopherol play a role in the primary prevention of heart disease and cancer? A review. Am. Coll. Nutr. 25 (2006) 292-299
8. Gysin R., Azzi A., and Visarius T. Gamma-tocopherol inhibits human cancer cell cycle progression and cell proliferation by down-regulation of cyclins. FASEB J. 16 (2002) 1952-1954
9. Jiang Q., Wong J., and Ames B.N. Gamma-tocopherol induces apoptosis in androgen-responsive LNCaP prostate cancer cells via caspase-dependent and independent mechanisms. Ann. N Y Acad. Sci. 1031 (2004) 399-400
10. Jiang Q., Wong J., Fyrst H., Saba J.D., and Ames B.N. gamma-Tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis. Proc. Natl. Acad. Sci. USA 101 (2004) 17825-17830
11. Campbell S.E., Stone W.L., Lee S., Whaley S., Yang H., Qui M., Goforth P., Sherman D., McHaffie D., and Krishnan K. Comparative effects of RRR-alpha- and RRR-gamma-tocopherol on proliferation and apoptosis in human colon cancer cell lines. BMC Cancer 6 (2006) 1-14
12. Stone W.L., Papas A.M., LeClair I.Q., Qui M., and Ponder T. The influence of dietary iron and tocopherols on oxidative stress and ras-p21 levels in the colon. Cancer Detect Prev. 26 (2002) 78-84
13. Jiang Q., Elson-Schwab I., Courtemanche C., and Ames B.N. Gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc. Natl. Acad. Sci. USA 97 (2000) 1149-1494
14. Campbell S.E., L Stone W., Whaley S.G., Qui M., and Krishnan K. Gamma tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma expression in SW 480 human colon cancer cell lines. BMC Cancer 3 (2003) 1-13
15. LeBlanc H.N., and Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10 (2003) 66-75
16. Kelley S.K., and Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. 4 (2004) 333-339
17. Ozören N., and El-Deiry W.S. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 4 (2002) 551-557
18. Roucou X., Montessuit S., Antonsson B., and Martinou J.C. Bax oligomerization in mitochondrial membranes requires tBid (caspase-8-cleaved Bid) and a mitochondrial protein. Biochem. J. 368 (2002) 915-921
19. Roucou X., and Martinou J.C. Conformational change of Bax: a question of life or death. Cell Death Differ. 8 (2001) 875-877
20. Yu W., Israel K., Liao Q.Y., Aldaz C.M., Sanders B.G., and Kline K. Vitamin E succinate (VES) induces Fas sensitivity in human breast cancer cells: role for Mr 43,000 Fas in VES-triggered apoptosis. Cancer Res. 59 (1999) 953-961
21. Yu W., Sanders B.G., and Kline K. RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells involves Bax translocation to mitochondria. Cancer Res. 63 (2003) 2483-2491
22. Cossarizza A., Baccarani-Contri M., Kalashnikova G., and Franceschi C.A. New method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem. Biophys. Res. Commun. 197 (1993) 40-45
23. Campos C.B., Paim B.A., Cosso R.G., Castilho R.F., Rottenberg H., and Vercesi A.E. Method for monitoring of mitochondrial cytochrome c release during cell death: immunodetection of cytochrome c by flow cytometry after selective permeabilization of the plasma membrane. Cytometry A 69 (2003) 515-523
24. Martin J.H., Potthoff A., Ledig S., Cornberg M., Jandl O., Manns M.P., Kubicka S., Flemming P., Athmann C., Beil W., and Wagner S. Effect of H. pylori on the expression of TRAIL, FasL and their receptor subtypes in human gastric epithelial cells and their role in apoptosis. Helicobacter 9 (2004) 371-386
25. Keane M.M., Ettenberg S.A., Nau M.M., Russell E.K., and Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59 (1999) 734-741
26. Singh T.R., Shankar S., Chen X., Asim M., and Srivastava R.K. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. 63 (2003) 5390-5400
27. Chinnaiyan A.M., Prasad U., Shankar S., Hamstra D.A., Shanaiah M., Chenevert T.L., Ross B.D., and Rehemtulla A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. USA 97 (2000) 1754-1759
28. Shankar S., and Srivastava R.K. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist. Updat. 7 (2004) 139-156
29. Nagane M., Huang H.J., and Cavenee W.K. The potential of TRAIL for cancer chemotherapy. Apoptosis 6 (2001) 191-197
30. Wang S., and El-Deiry W.S. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22 (2003) 8628-8633
31. Shankar S., Singh G., and Srivastava R.K. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci. 12 (2007) 4839-4854
32. Fulda S., and Debatin K.M. Resveratrol-mediated sensitization to TRAIL-induced apoptosis depends on death receptor and mitochondrial signaling. Eur. J. Cancer 41 (2005) 786-798
33. Tomasetti M., Rippo M.R., Alleva R., Moretti S., Andera L., Neuzil J., and Procopio A. Alpha-tocopheryl succinate and TRAIL selectively synergize in induction of apoptosis in human malignant mesothelioma cells. Br. J. Cancer 90 (2004) 1644-1653
34. Zou W., Liu X., Yue P., Zhou Z., Sporn M.B., Lotan R., Khuri F.R., and Sun S.-Y. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res. 64 (2004) 7570-7578
35. Yu W., Simmons-Menchaca M., Gapor A., Sanders B.G., and Kline K. Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols. Nutr. Cancer 33 (1999) 26-32
36. Takimoto R., and El-Deiry W.S. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19 (2000) 1735-1743
37. Shetty S., Graham B.A., Brown J.G., Hu X., Vegh-Yarema N., Harding G., Paul J.T., and Gibson S.B. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol. Cell Biol. 25 (2005) 5404-5416
38. Wang Y., Engels I.H., Knee D.A., Nasoff M., Deveraux Q.L., and Quon K.C. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 5 (2004) 501-512
39. Barnhart B.C., Alappat E.C., and Peter M.E. The CD95 type I/type II model. Semin. Immun. 115 (2003) 185-193